ProQR Therapeutics N.V. (PRQR)
| Market Cap | 155.93M |
| Revenue (ttm) | 19.19M |
| Net Income (ttm) | -49.53M |
| Shares Out | 105.36M |
| EPS (ttm) | -0.47 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,716,996 |
| Open | 1.480 |
| Previous Close | 1.490 |
| Day's Range | 1.410 - 1.580 |
| 52-Week Range | 1.330 - 3.100 |
| Beta | 0.09 |
| Analysts | Strong Buy |
| Price Target | 6.80 (+359.46%) |
| Earnings Date | May 7, 2026 |
About PRQR
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metab... [Read more]
Financial Performance
In 2025, ProQR Therapeutics's revenue was 16.35 million, a decrease of -16.36% compared to the previous year's 19.55 million. Losses were -42.18 million, 51.9% more than in 2024.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for PRQR stock is "Strong Buy." The 12-month stock price target is $6.8, which is an increase of 359.46% from the latest price.
News
ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies ba...
ProQR Therapeutics Transcript: Status update
AX-0810 is advancing in cholestatic diseases with key data expected soon and biliary atresia as the lead phase II indication. Next-gen programs like AX-0811 and AX-0422 show strong preclinical results, while AI-driven discovery and strategic partnerships support a robust pipeline and financial runway into mid-2027.
ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board
ProQR and Ginkgo Bioworks to collaborate on autonomous lab high throughput data generation to support ProQR's AI-enabled drug discovery for Axiomer™ ProQR establishes AI Advisory Board with leaders fr...
ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
ProQR Announces Year End 2025 Operating and Financial Results
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies ba...
ProQR Therapeutics Transcript: The Citizens Life Sciences Conference 2026
The company is advancing its proprietary RNA editing platform, with lead program AX-0810 in phase I for cholestatic diseases and additional candidates in Rett syndrome and fatty liver disease. Key data readouts and milestones are expected in 2024, supported by a strong cash position and strategic partnerships.
ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
ProQR Announces Planned Changes to Board Composition
LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook
Initial AX-0810 data show no safety signals after 4 weeks of dosing and pharmacokinetics consistent with non-clinical data; Phase 1 enrollment and dosing in healthy volunteers ongoing with target enga...
ProQR Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference
The company is advancing RNA editing therapies, highlighted by a lead program for cholestatic diseases with a phase 1 trial underway and initial data expected soon. Indication selection for phase 2 will follow, and a Rett syndrome program is progressing toward clinical candidate selection.
ProQR to Participate in 8th Annual Evercore Healthcare Conference
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies bas...
ProQR Announces Third Quarter 2025 Operating and Financial Results
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies ba...
ProQR Therapeutics Transcript: Study Update
AX-0810, a first-in-class RNA editing therapy targeting NTCP, has entered phase I trials in healthy volunteers to address cholestatic diseases. The study uses robust biomarker strategies to assess target engagement and safety, with initial data expected by year-end and patient cohorts planned for PSC.
ProQR Therapeutics Transcript: Chardan’s 9th Annual Genetic Medicines Conference
Panelists highlighted rapid clinical progress in ADAR RNA editing, with lead programs in AATD showing durable, physiologically relevant protein correction and new targets like NTCP and PNPLA3 advancing. The field is maturing quickly, with robust chemistry, delivery, and target selection strategies supporting broad future applications.
ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025
LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies bas...
ProQR to Participate in Upcoming Investor Conferences in October 2025
LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies bas...
ProQR Announces Second Quarter 2025 Operating and Financial Results
LEIDEN, Netherlands & CAMBRIDGE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies ba...
ProQR Announces Upcoming Presentation at RNA Editing Summit
LEIDEN, Netherlands & CAMBRIDGE, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based...
ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based...
ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based ...
ProQR Therapeutics Transcript: The Citizens JMP Life Sciences Conference 2025
A novel RNA editing platform is advancing toward clinical trials, with a lead program targeting cholestatic liver diseases and several additional programs in cardiovascular, CNS, and metabolic indications. Strategic partnerships and a strong cash position support a robust pipeline and anticipated clinical milestones this year.
ProQR Announces First Quarter 2025 Operating and Financial Results
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies base...
ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based...
ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 14, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV.